Hypertension (High Blood Pressure) News and Research

RSS

Hypertension (or high blood pressure) is a condition where the pressure of the blood flowing through the arteries of the body is higher than it should be. Much like the pressure of the air in a tire, if the pressure of the blood is too high it can damage the arteries and organs of the body. Just like the tire, if the pressure suddenly becomes very high, catastrophic events can happen. Similarly, if the pressure remains somewhat elevated for a long enough period of time, premature wear and failure can occur.

Hypertension has its worst effects on the heart, kidneys, eyes, and brain. High blood pressure is a risk factor for heart attack, stroke, kidney failure, hemorrhages of the retina of the eye, and generalized atherosclerosis (hardening of the arteries all over the body).

FDA approves Novartis' Amturnide for treatment of high blood pressure

Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

23 Dec 2010

Excessive carbohydrates, rather than fat, may be the source of America's dietary woes

A growing number of top nutritional scientists are pointing to excessive carbohydrates, rather than fat, as the source of America's dietary woes. As reported in the Los Angeles Times on December 20, some researchers are saying that cutting carbohydrates is the key to reversing obesity, heart disease, Type 2 diabetes and hypertension.

22 Dec 2010

Top ten advances in cardiovascular, stroke research in 2010

Research on reducing risks, improving medical treatment and improving lifestyle behaviors to fight the battle against heart disease and stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research recognized by the American Heart Association/American Stroke Association.

22 Dec 2010

Moderately and morbidly obese drivers face increase risk of death during severe vehicle crashes

Moderately and morbidly obese persons face many health issues -- heart disease, diabetes, hypertension, stroke, gallbladder disease and others. Now, increased chances of dying while driving during a severe auto accident can be added to the list.

22 Dec 2010

3M sues Andover for patent infringement over two layer compression bandage systems

3M and 3M Innovative Properties Co. filed a lawsuit in the U.S. District Court for the District of Minnesota today against Andover Healthcare Inc. seeking a preliminary injunction as well as a permanent injunction and damages regarding Andover's two layer compression bandage systems.

22 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

Chelsea Therapeutics International, Ltd. announced it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA™(droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.

20 Dec 2010

FDA moves to curb Avastin's approval for breast cancer

The Food and Drug administration on Thursday revoked its approval of Roche drug Avastin for the treatment of breast cancer. The agency's action, based on findings that did not confirm that the medicine helped patients with this disease, has drawn criticism from patients and politicians.

20 Dec 2010

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Oxygen Biotherapeutics, Inc. and privately held Sarasota Medical Products, Inc. (SMP) of Sarasota, FL, today announced they signed a Binding Letter of Intent to determine the feasibility of pursuing a joint research and development venture for treating chronic ischemic wounds. The venture will be based on combining Oxygen's Wundecyte™ PFC formulation with SMP's topical medical devices.

16 Dec 2010

Innovative research investigates importance of reading to newborns in the NICU

The first few days after birth is an important time when babies learn to recognize the sound of their parents' voice and the parents in turn bond with their children. However, the separation between parents and newborns admitted to the intensive care unit can be very difficult and can disrupt the early development of this relationship.

15 Dec 2010

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

An independent, national survey reveals 40 percent of consumers prefer to shop for and purchase vision correction services during evenings or weekends.

15 Dec 2010

HUP launches Penn Hand Transplant Program

The Penn Transplant Institute, the Department of Orthopaedic Surgery and the Division of Plastic Surgery at the Hospital of the University of Pennsylvania (HUP) have collaborated to form the Penn Hand Transplant Program.

15 Dec 2010

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS, Inc. today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010. The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

14 Dec 2010

Workplace interactions may educate people about organ donation process

Face-to-face workplace interactions may be the best way to educate and encourage people to consider becoming organ donors, according to new research from Purdue University.

14 Dec 2010

We live longer, but not healthier

Increased life expectancy in the United States has not been accompanied by more years of perfect health, reveals new research published in the December issue of the Journal of Gerontology.

14 Dec 2010

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

Medicare patients with a host of physical problems are getting better care at the University of Michigan Health System, and U-M staff have saved more than $15 million on the cost of that care over four years.

13 Dec 2010

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Results of the GeparQuinto study, randomized Phase III efficacy data on the use of bevacizumab plus chemotherapy to treat women with early breast cancer will be presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

13 Dec 2010

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

Pfizer Inc. announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide.

10 Dec 2010

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

10 Dec 2010

FDA approves Mylan's generic Adalat CC Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Nifedipine Extended-release Tablets USP, 30 mg, 60 mg and 90 mg, the generic version of Bayer's Adalat® CC Tablets, a treatment for hypertension.

10 Dec 2010

Hypertension (High Blood Pressure) News and Research

Further Reading

FDA approves Novartis' Amturnide for treatment of high blood pressure

Excessive carbohydrates, rather than fat, may be the source of America's dietary woes

Top ten advances in cardiovascular, stroke research in 2010

Moderately and morbidly obese drivers face increase risk of death during severe vehicle crashes

3M sues Andover for patent infringement over two layer compression bandage systems

VIVUS seeks marketing approval of QNEXA in the EU

Chelsea completes successful NORTHERA pre-NDA assessment with FDA

FDA moves to curb Avastin's approval for breast cancer

Oxygen Biotherapeutics and SMP sign Binding Letter of Intent for joint chronic ischemic wound research

Innovative research investigates importance of reading to newborns in the NICU

Survey reveals 40% of consumers prefer to purchase vision care services during weekends, evenings

HUP launches Penn Hand Transplant Program

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

Workplace interactions may educate people about organ donation process

We live longer, but not healthier

U-M's participation in Medicare Physician Group Practice Demonstration Project helps save over $15 million

GeparQuinto study data on bevacizumab plus chemotherapy in early breast cancer to be presented at 33rd CTRC-AACR

Pfizer withdraws Thelin for treatment of PAH, discontinues global clinical studies

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

FDA approves Mylan's generic Adalat CC Tablets ANDA

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News